IGM Biosciences to cut 73% of workforce
IGM Biosciences has halted all oncology programs and faces a significant pipeline upheaval. Read why I maintain my Sell ...
Hosted on MSN9h
Stifel Downgrades IGM Biosciences (IGMS)Fintel reports that on January 10, 2025, Stifel downgraded their outlook for IGM Biosciences (NasdaqGS:IGMS) from Buy to Hold ...
Staff cuts could leave IGM Biosciences with fewer than 55 employees. The company is also halting development of two ...
Just two weeks into 2025, January is proving why it’s earned a reputation as the worst month for layoffs. | Just two weeks ...
JPMorgan upgraded IGM Biosciences (IGMS) to Neutral from Underweight without a price target The firm says that with the company announcing ...
IGM Biosciences (IGMS) is slashing its workforce by 73% and discontinuing development of two of its lead drug candidates in ...
GlobalData on MSN1d
IMG Biosciences enacts massive lay-offs after Phase I trial failureFollowing the negative Phase I trial outcome for its autoimmune disease treatment, the company is cutting 73% of jobs.
IGM Biosciences announced the discontinuation of imvotamab and IGM-2644 for autoimmune and inflammatory diseases, including ...
IGM Biosciences (IGMS) stock faces sharp selloff as the company abandons two therapeutic candidates, triggering Wall Street ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback